Imbalance in serum soluble CD30/CD30L and CD40/CD40L systems are associated with ovarian tumors.
The aim of the study was to examine the concentrations of the soluble receptors and their ligands of CD30/CD30L and CD40/CD40L systems in the serum of women with ovarian tumor and in the ovarian cyst fluid of women with Cystadenoma serosum. The study included 120 women with ovarian tumors. As a control, sera were obtained from 60 healthy female volunteers. Concentrations of the sCD30, sCD30L, sCD40 and sCD40L in the serum and the ovarian cyst fluid were measured by ELISA enzyme-linked immunosorbent assay. Concentrations of both sCD30 and sCD30L in serum of women with ovarian tumors were significantly higher than in control (p < 0.0001). The highest serum receptor and its ligand levels were observed in women with ovarian cancer (p < 0.0001). Moreover, results showed significantly increased levels of sCD40 and sCD40L serum in women with ovarian tumors, as compared to the control group (p < 0.0001). The highest concentration of sCD40 in the serum of women with ovarian cancer and sCD40L in serum of women with Teratoma maturum (p < 0.0001) were observed. Impaired apoptosis among women with ovarian tumors is associated with the impairments of soluble CD30/CD30L and CD40/CD40L systems. Measurement of studied parameter concentrations in serum of women with ovarian tumors has been suggested to be a potential tool in monitoring of inflammatory. Evaluation of sCD30, sCD30L and sCD40 might be an early diagnostic marker in patients with the ovarian cancer. Concentrations of the studied parameters in the ovarian cyst fluid higher than the serum values suggest local suppression of the immune response. However, the final evaluation of the importance of measurement of serum levels of them requires further investigation.
Department of Immunology and Serology, Medical University of Silesia, Raciborska 15, 40-074 Katowice, Poland. apalacz@sum.edu.pl
Aleksandra
A
Mielczarek-Palacz
Justyna
J
Sikora
Zdzisława
Z
Kondera-Anasz
Grzegorz
G
Hauza
D000328:Adult; D053285:CD30 Ligand / Q000097:blood*; D019013:CD40 Antigens / Q000097:blood*; D023201:CD40 Ligand / Q000097:blood*; D016022:Case-Control Studies; D018284:Cystadenocarcinoma, Serous / Q000097:blood* / Q000175:diagnosis; D018293:Cystadenoma, Serous / Q000097:blood* / Q000175:diagnosis; D005260:Female; D006801:Humans; D017730:Ki-1 Antigen / Q000097:blood*; D008875:Middle Aged; D010048:Ovarian Cysts / Q000737:chemistry; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis; D012995:Solubility; D013724:Teratoma / Q000097:blood* / Q000175:diagnosis
D053285:CD30 Ligand; D019013:CD40 Antigens; D017730:Ki-1 Antigen; D023201:CD40 Ligand